Market Overview

KBW Is Downgrading Stonegate Mortgage


In a report published Tuesday, Keefe, Bruyette & Woods analysts downgraded the rating on Stonegate Mortgage Corp (NYSE: SGM) from Outperform to Market Perform, while maintaining a price target of $12.50. The downgrade comes in the wake of recent run-up in the company's share price.

Stonegate Mortgage continues to be fundamentally sound but its shares have surged more than 20 percent since the company reported its 4Q results. "SGM shares currently trade at 1.05x book value, which means limited upside to our $12.50 price target," the analysts mentioned.

In the last two quarters, SGM had missed street estimates due to lower interest rate locks and the consequent reduced gain-on-sale income. However, the increase in applications in 1Q suggest a spike in interest rate locks in 1Q.

"Stronger-than-expected mortgage volume or a smaller-than-expected MSR mark may act as catalysts and boost the company's performance in the near future," the analysts stated.

Higher volumes and better gain on sale income is expected to boost Stonegate Mortgage's sequential operating EPS. The 1Q15 GAAP estimate has been reduced to $(0.32) per share to incorporate a $15 million MSR mark. The operating estimates for 2015 and 2016 have been left unchanged at $0.55 and $1.21, respectively.

Latest Ratings for SGM

Oct 2016Initiates Coverage OnBuy
Mar 2016MaintainsUnderweight
Jan 2016DowngradesOutperformNeutral

View More Analyst Ratings for SGM
View the Latest Analyst Ratings

Posted-In: Keefe Bruyette & WoodsAnalyst Color Downgrades Analyst Ratings


Related Articles (SGM)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals

The Top 100 People To Follow On Twitter For Financial News